Cardiac resynchronization therapy is evolving with new guidelines for indications, including patients with NYHA Class I and normal QRS duration.
This review summarizes the 2013 state of the art for cardiac resynchronization therapy, including updated guidelines, new potential indications, and unresolved technical and clinical issues.
Cardiac resynchronization therapy (CRT) is currently an established device therapy for heart failure (HF) patients. Cumulated knowledge on the pathophysiological mechanisms, implantation techniques, advancement of device-based technologies, and clinical trial experience has impacted on this evolving therapy significantly in the last few years. This article will address the updated CRT guideline and potentially new indications of CRT such as patients with New York Heart Association Class I, normal QRS duration, and non-HF patients with pacing indications. Furthermore, important but unresolved issues will also be discussed which include the impact of QRS morphology and QRS duration on CRT response, new approaches for placement of left ventricular (LV) lead, multisite LV pacing, and the role of HF disease monitoring program.
Yu et al. (2013) studied this question. Cardiac resynchronization therapy is evolving with new guidelines for indications, including patients with NYHA Class I and normal QRS duration.